MATINAS BIOPHARMA HOLDINGS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- MATINAS BIOPHARMA HOLDINGS, INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $0.00.
- MATINAS BIOPHARMA HOLDINGS, INC. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $309.00K, a 96.64% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $21.00K, a 61.11% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. stock issued during period, value, new issues for the quarter ending 2024-12-31 was $0.00.
- MATINAS BIOPHARMA HOLDINGS, INC. stock issued during period, value, new issues for fiscal 2024 was $9.18M.
- MATINAS BIOPHARMA HOLDINGS, INC. stock issued during period, value, new issues for fiscal 2021 was $5.58M, a 88.05% decline from fiscal 2020.
- MATINAS BIOPHARMA HOLDINGS, INC. stock issued during period, value, new issues for fiscal 2020 was $46.70M, a 55.15% increase from fiscal 2019.
- MATINAS BIOPHARMA HOLDINGS, INC. stock issued during period, value, new issues for fiscal 2019 was $30.10M, a 332.10% increase from fiscal 2018.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $330.00K derived: sum of 4 quarters · filed 2026-03-31 |
| 2025-06-30 | $309.00K 10-Q · filed 2025-08-14 | $265.00K derived: sum of 4 quarters · filed 2026-03-31 |
| 2025-03-31 | $21.00K 10-Q · filed 2025-05-15 | $9.15M derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $9.18M 10-K · filed 2026-03-31 |
| 2024-09-30 | -$65.00K 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $9.19M 10-Q · filed 2025-08-14 | |
| 2024-03-31 | $54.00K 10-Q · filed 2025-05-15 | |
| 2021-12-31 | $529.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $5.58M 10-K · filed 2023-03-15 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $5.58M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $5.58M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $5.58M 10-Q · filed 2022-05-12 | $5.59M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-11 | $46.70M 10-K/A · filed 2022-03-11 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $46.70M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $46.70M derived: sum of 4 quarters · filed 2021-03-29 |
| 2020-03-31 | $46.69M 10-Q · filed 2020-05-11 | $46.63M derived: sum of 4 quarters · filed 2021-03-29 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $30.10M 10-K · filed 2021-03-29 |
| 2019-09-30 | -$1.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $30.10M derived: sum of 4 quarters · filed 2020-05-11 |
| 2019-06-30 | -$65.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $30.01M derived: sum of 4 quarters · filed 2020-05-11 |
| 2019-03-31 | $30.17M 10-Q · filed 2020-05-11 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $6.97M 10-K · filed 2019-04-01 |
| 2018-09-30 | -$89.58K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | |
| 2016-12-31 | $8.00M 10-K · filed 2018-03-16 | |
| 2013-12-31 | $375.00K 10-Q · filed 2015-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |